Recruiting
Phase 1
Phase 2

AD-PluReceptor with Tafasitamab-cxix

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT06434363

Conditions

Autoimmune Disorders

Systemic Sclerosis

Systemic Lupus Erythematosus

Lupus

Lupus Nephritis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Tafasitamab

Fludarabine phosphate

Cyclophosphamide

Tafasitamab and NK cells

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-17. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-07-23.